Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial
Adding immunotherapy to a kidney cancer treatment benefits patients who've already failed one drug, expanding rescue options in resource-limited settings.
This Phase 2 study of camrelizumab plus apatinib in 41 ICI-naive metastatic RCC patients who failed first-line TKI therapy achieved a median PFS of 11.6 months and ORR of 41.5%, suggesting this IO+TKI combination may be a viable rescue strategy for a population where sequential therapy options are limited. The study provides prospective evidence in a gap (second-line IO after TKI failure) that is increasingly common due to first-line TKI monotherapy use in limited-resource settings.
What the study was
- Study design
- Single-arm two-center Phase 2 trial
- Population
- ICI-naive metastatic clear cell RCC patients after first-line TKI failure; n=41
- Sample size
- 41
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- BMC Medicine
Why it surfaced
Prospective Phase 2 data for IO+TKI combination in ICI-naive post-first-line TKI RCC; addresses a real clinical gap; n=41 limits generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.